Navigation Links
Cord Blood America CEO and Co-Founder Matthew Schissler Named Chairman of Biotech Committee for Nevada Development Authority

LAS VEGAS, Feb. 1, 2011 /PRNewswire/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI) ( has announced that Cord Blood America's CEO and Co-Founder Matthew Schissler has been named chairman of the Biotech Committee for the Nevada Development Authority.  The Biotech Committee is charged with developing programs and initiatives to help attract new biotech businesses to Southern Nevada and help existing biotech companies expand in the area.

"I am honored to be named chairman of the Biotech Committee for the Nevada Development Authority  and look forward to working with the committee to help attract new biotech businesses and expand existing ones in Southern Nevada," said Mr. Schissler.

He added, "Moving Cord Blood America to Southern Nevada 18 months ago was one of the best decisions in our history.  Nevada is extremely business friendly through low tax rates, laws and regulations.  Access to one of the busiest airports in the country, ease of getting around with little traffic or infrastructure issues, and the low cost of real estate and living were the key decision points for us.  Couple those with world-class accommodations, entertainment, millions of people attending conventions, and more than 20 percent of the top 100-rated restaurants in the country being on The Strip, and you have a recipe for an unsurpassed business environment.  I look forward to delivering this message to the thousands of domestic and international biotechs looking for a place to call home."

Somer Hollingsworth, president and CEO of the NDA, said Mr. Schissler is an asset to the NDA and will serve as a strong ambassador for the biotech and related industries.

"Now more than ever is a crucial time in Nevada's history to become increasingly proactive in attracting new businesses to our state," Mr. Hollingsworth said. "The biotech sector is a natural fit for Nevada, and we are relishing the fact that companies like Cord Blood America are realizing the advantages Nevada has to offer and are stepping up efforts to be a voice for our state."

About Cord Blood AmericaCord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of diseases, including cancer, leukemia, blood and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit For investor information, visit

About Nevada Development AuthorityThe Nevada Development Authority is a non-profit agency that works to diversify and improve the economy of Southern Nevada. Established in Las Vegas in 1956, the NDA is dedicated to fostering an attractive, business-friendly environment through building key relationships while assisting and targeting new and expanding businesses.  The mission of the NDA is to attract, retain and expand the business base and enhance the overall socioeconomic development of Southern Nevada. CONTACT:Paul KnopickE & E Communications949/

SOURCE Cord Blood America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
2. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
3. Limbs saved by menstrual blood stem cells
4. Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes
5. Human Trial Results Show Plant Extract Tops Drug at Regulating Blood Sugar Levels; Huge Market Seen for Newly Developed Food Additive Emulin™
6. No Blood Needed Thanks to Innovative Medical Technology
7. The Modern DeBakey VAD™ To Be Introduced For the First Time in the U.S. : HeartAssist 5™ Pediatric VAD Features Industry Exclusive Direct Blood Flow Measurement System
8. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
9. CORD:USE Cord Blood Bank is Proud to Announce that Cord Blood Pioneer and Leading Transplanter Dr. Eliane Gluckman has Joined its Team
10. American Red Cross Expands Agreement for Strategic Blood Management(TM) Services from Strategic Healthcare Group LLC
11. China Biologic Products Enters Into Agreement to Acquire 35% Interest in Xian Huitian Blood Products Co., Ltd. and Introduces Preliminary Guidance for 2009
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... International Society for ... of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference ... ISPE hosted the largest number of attendees in more than a decade. ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)... SHPG ) announced today that Jeff Poulton , Chief ... Annual Healthcare Conference in New York City , ... p.m. GMT). --> SHPG ) announced today that ... Jaffray 27 th Annual Healthcare Conference in New ... 8:30 a.m. EST (1:30 p.m. GMT). --> Shire plc ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... today that the remaining 11,000 post-share consolidation (or ... Warrants (the "Series B Warrants") subject to the ... on November 23, 2015, which will result in ... giving effect to the issuance of such shares, ...
Breaking Biology Technology:
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/27/2015)... , October 27, 2015 ... Automated Semantic Gaze Mapping technology (ASGM) automatically maps data ... Eye Tracking Glasses , so that they can ... --> Munich, Germany , October ... automatically maps data from mobile eye tracking videos created ...
Breaking Biology News(10 mins):